

Biogen to Report First Quarter 2019 Financial Results April 24, 2019

March 13, 2019

Cambridge, Mass. —Biogen Inc. (Nasdaq:BIIB) today announced it will report first quarter 2019 financial results Wednesday, April 24, 2019, before the financial markets open.

Following the release of the financials, the Company will host a live webcast with Biogen management from 8:00-9:00 am ET. To access the live webcast, please go to the investors section of Biogen's website at http://investors.biogen.com/. Following the live webcast, an archived version of the call will be available on the website.

About Biogen

At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. One of the world's first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp, and today has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is focused on advancing neuroscience research programs in Alzheimer's disease and dementia, MS and neuroimmunology, movement disorders, neuromuscular disorders, acute neurology, neurocognitive disorders, pain, and ophthalmology. Biogen also manufactures and commercializes biosimilars of advanced biologics.

We routinely post information that may be important to investors on our website at www.biogen.com. To learn more, please visit www.biogen.com and follow us on social media — Twitter, LinkedIn, Facebook, youTube.

Contact: Karen Jewell Investor Relations Biogen 781.464.2442